Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges

References

• Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103; PMID:21046175; http://dx.doi.org/10.1007/s00705-010-0814-x
   PubMed Web of Science ®Google Scholar
• Kuhn JH. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch Virol Suppl 2008; 20:13-360; PMID:18637412; http://dx.doi.org/10.1007/978-3-211-69495-4_1
   PubMedGoogle Scholar
• Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, Swanepoel R, Paddock CD, Balinandi S, Khristova ML, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Path 2009; 5:e1000536; PMID:19649327; http://dx.doi.org/10.1371/journal.ppat.1000536
   PubMed Web of Science ®Google Scholar
• Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska JT, Gonzalez JP, Swanepoel R. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6; PMID:16319873; http://dx.doi.org/10.1038/438575a
   PubMed Web of Science ®Google Scholar
• Feldmann H, Klenk HD, Sanchez A. Molecular biology and evolution of filoviruses. Arch Virol Suppl 1993; 7:81-100; PMID:8219816; http://dx.doi.org/10.1007/978-3-7091-9300-6_8
   PubMedGoogle Scholar
• Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 1993; 29:215-40; PMID:8237108; http://dx.doi.org/10.1016/0168-1702(93)90063-S
   PubMed Web of Science ®Google Scholar
• Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996; 93:3602-7; PMID:8622982; http://dx.doi.org/10.1073/pnas.93.8.3602
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Becker S, Volchkova VA, Ternovoj VA, Kotov AN, Netesov SV, Klenk HD. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214:421-30; PMID:8553543; http://dx.doi.org/10.1006/viro.1995.0052
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998; 95:5762-7; PMID:9576958; http://dx.doi.org/10.1073/pnas.95.10.5762
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196 Suppl 2:S404-12; PMID:17940977; http://dx.doi.org/10.1086/520591
   PubMedGoogle Scholar
• Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006; 80:2267-79; PMID:16474134; http://dx.doi.org/10.1128/JVI.80.5.2267-2279.2006
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7; PMID:18216185; http://dx.doi.org/10.1128/CVI.00431-07
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9; PMID:11117750; http://dx.doi.org/10.1038/35046108
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4; PMID:12904795; http://dx.doi.org/10.1038/nature01876
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37; PMID:9813200; http://dx.doi.org/10.1006/viro.1998.9367
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007; 196 Suppl 2:S421-9; http://dx.doi.org/10.1086/520612
   PubMed Web of Science ®Google Scholar
• Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408-12; PMID:12021376; http://dx.doi.org/10.1128/JVI.76.12.6408-6412.2002
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034-9; PMID:22411795; http://dx.doi.org/10.1073/pnas.1200409109
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81; PMID:22700957; http://dx.doi.org/10.1126/scitranslmed.3003876
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013; 110:1893-8; PMID:23319647; http://dx.doi.org/10.1073/pnas.1209591110
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17:1128-31; PMID:21857654; http://dx.doi.org/10.1038/nm.2447
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80; PMID:12922144; http://dx.doi.org/10.1016/S0264-410X(03)00362-1
   PubMed Web of Science ®Google Scholar
• Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003; 92:187-93; PMID:12686428; http://dx.doi.org/10.1016/S0168-1702(02)00338-6
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vacc Immunother 2012; 8:1703-6; PMID:22922764; http://dx.doi.org/10.4161/hv.21873
   PubMed Web of Science ®Google Scholar
• Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol 2013; 4:267; PMID:24046765; http://dx.doi.org/10.3389/fmicb.2013.00267
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, Smith JF, Jahrling PB, Schmaljohn AL. Marburg virus vaccines: comparing classical and new approaches. Vaccine 2001; 20:586-93; PMID:11672925; http://dx.doi.org/10.1016/S0264-410X(01)00353-X
   PubMed Web of Science ®Google Scholar
• Schmaljohn CS, Spik KW, Hooper JW. DNA vaccines for HFRS: laboratory and clinical studies. Virus Res 2014; 187:91-6; PMID:24370868; http://dx.doi.org/10.1016/j.virusres.2013.12.020
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18:707-16; PMID:21450977; http://dx.doi.org/10.1128/CVI.00030-11
   PubMed Web of Science ®Google Scholar
• Spik KW, Badger C, Mathiessen I, Tjelle T, Hooper JW, Schmaljohn C. Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters. Vaccine 2008; 26:5177-81; PMID:18482782; http://dx.doi.org/10.1016/j.vaccine.2008.03.097
   PubMed Web of Science ®Google Scholar
• Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, Hannaman D, Schmaljohn C. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect 2014; 20 Suppl 5:110-7; PMID:24447183; http://dx.doi.org/10.1111/1469-0691.12553
   PubMed Web of Science ®Google Scholar
• Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, Loudon P, Rusnak J, Rivard R, Schmaljohn C, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine 2012; 30:1951-8; PMID:22248821; http://dx.doi.org/10.1016/j.vaccine.2012.01.024
   PubMed Web of Science ®Google Scholar
• Hooper JW, Josleyn M, Ballantyne J, Brocato R. A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 2013; 31:4314-21; PMID:23892100; http://dx.doi.org/10.1016/j.vaccine.2013.07.025
   PubMed Web of Science ®Google Scholar
• Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW. Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine. Clin Vaccine Immunol 2013; 20:218-26; PMID:23239797; http://dx.doi.org/10.1128/CVI.00546-12
   PubMed Web of Science ®Google Scholar
• Kwilas S, Kishimori JM, Josleyn M, Jerke K, Ballantyne J, Royals M, Hooper JW. A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates. Curr Gene Ther 2014; 14:200-10; PMID:24867065; http://dx.doi.org/10.2174/1566523214666140522122633
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 2010; 28:7345-50; PMID:20851089; http://dx.doi.org/10.1016/j.vaccine.2010.09.005
   PubMed Web of Science ®Google Scholar
• Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 2010; 84:2972-82; PMID:20053739; http://dx.doi.org/10.1128/JVI.02151-09
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010; 401:228-35; PMID:20304456; http://dx.doi.org/10.1016/j.virol.2010.02.029
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6; PMID:10698744; http://dx.doi.org/10.1126/science.287.5458.1664
   PubMed Web of Science ®Google Scholar
• Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, et al. Emergence of Zaire Ebola Virus Disease in Guinea – Preliminary Report. N Engl J Med 2014; 371(15):1418-25; PMID:24738640
   PubMed Web of Science ®Google Scholar
• Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Path 2012; 8:e1003065; PMID:23271969; http://dx.doi.org/10.1371/journal.ppat.1003065
   PubMed Web of Science ®Google Scholar
• Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Path 2007; 3:e9; PMID:17238286; http://dx.doi.org/10.1371/journal.ppat.0030009
   PubMed Web of Science ®Google Scholar
• Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PloS One 2012; 7:e36192; PMID:22558378; http://dx.doi.org/10.1371/journal.pone.0036192
   PubMed Web of Science ®Google Scholar
• Olinger GG, Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Pro Nat Acad Sci U S A 2012; 109:18030-5; PMID:23071322; http://dx.doi.org/10.1073/pnas.1213709109
   PubMed Web of Science ®Google Scholar
• Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541-4; PMID:890413; http://dx.doi.org/10.1136/bmj.2.6086.541
   PubMed Web of Science ®Google Scholar
• Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 Suppl 1:S18-23; PMID:9988160; http://dx.doi.org/10.1086/514298
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514(7520):47-53; PMID:25171469
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66; PMID:16973570; http://dx.doi.org/10.1128/JVI.00959-06
   PubMed Web of Science ®Google Scholar
• Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82; PMID:18615077; http://dx.doi.org/10.1038/nature07082
   PubMed Web of Science ®Google Scholar
• Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A, Kawaoka Y, Yoshimatsu K, Arikawa J. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diag Lab Immunol 2003; 10:154-60; PMID:12522053
   PubMedGoogle Scholar